[NSCLC and new oncogenic mutations: Diagnosis and perspectives]. / Carcinome bronchique non à petites cellules : nouvelles addictions oncogéniques, diagnostic et perspectives.
Rev Mal Respir
; 38(5): 477-488, 2021 May.
Article
em Fr
| MEDLINE
| ID: mdl-34020835
ABSTRACT
The development of new targeted therapies in non-small cell lung carcinoma (NSCLC) depends on a better understanding of the molecular basis of carcinogenesis, a knowledge of the role of molecular aberrations in disease progression and the development of molecular biology platforms with the capacity to identify new biomarkers. In the current article, we review the techniques routinely used in cancer molecular biology platforms as well as new techniques under development. These new NSCLC biomarkers have been made available to clinicians and biologists in parallel with the development of targeted drugs. New molecular abnormalities of EGFR exon 20, HER2, MET, RET, BRAF, ROS1 and NTRK have been identified and there have been clinical trials of the most innovative targeted drugs.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Idioma:
Fr
Ano de publicação:
2021
Tipo de documento:
Article